Triple combination appears safe, effective for advanced BRAF V600-mutant melanoma

Source: Healio, December 2018

NEW YORK — The addition of spartalizumab to dabrafenib and trametinib appeared safe and effective for previously untreated patients with advanced BRAF V600-mutant unresectable or metastatic melanoma, according to study results presented at Chemotherapy Foundation Symposium.

All nine evaluated patients achieved a confirmed response. In addition, the safety profile for the triplet regimen appeared consistent with that observed in prior studies of these agents.

Targeted therapy and immune checkpoint inhibitors have greatly improved outcomes for patients with unresectable or metastatic BRAF V600-mutated melanoma.